Jemma Arakelyan, Chief Executive Officer at The Institute of Cancer and Crisis (ICC) and Medical Advisor at Immune Oncology Research Institute, shared a post on LinkedIn:
“Just finished The National Institutes of Health Clinical Research program, and I am so thankful to the program directors for this amazing opportunity to learn!
This is a completely comprehensive course. From the historic roots of clinical research (and how we got where we are today) to current-day FDA and EMA drug regulations, providing a complete education on designing/reporting clinical trials, and last but certainly not least, conducting research ethically to make sure the patient gets the benefit they deserve.
At the end of the day, though, I keep coming back to what Dr. John Gallin said at the start of his talk:
‘It’s a business – and it’s a dangerous business for patients.’
That brings us back to the very first principle we learn in medical school:
Primum non nocere. First, do no harm.
Whether you’re just starting out in your career or you’ve already spent years as a clinician/investigator, there is something for everyone here.
A huge recommendation to anyone who works in clinical research.”
Other articles featuring Jemma Arakelyan on OncoDaily.